{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:33:48Z","timestamp":1794893628516,"version":"4.9.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003107","name":"German Federal Ministry of Health","doi-asserted-by":"publisher","award":["031A428D"],"award-info":[{"award-number":["031A428D"]}],"id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017177","name":"Deutscher Akademischer Austauschdienst France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017177","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","award":["57378443"],"award-info":[{"award-number":["57378443"]}],"id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.annonc.2021.08.1991","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T22:44:13Z","timestamp":1629758653000},"page":"1400-1409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-\/triple-hit status"],"prefix":"10.1016","volume":"32","author":[{"given":"G.A.","family":"Croci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.K.H.","family":"Au-Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Reinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Staiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Oschlies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Poeschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rosenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Spang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Altmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ziepert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.annonc.2021.08.1991_bib1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.annonc.2021.08.1991_bib2","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.annonc.2021.08.1991_bib3","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood-2002-07-2298","article-title":"A\u00a0significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival","volume":"101","author":"Hans","year":"2003","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.annonc.2021.08.1991_bib4","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO.2016.70.3660","article-title":"Clinical impact of the cell-of-origin classification and the MYC\/BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German high-grade non-Hodgkin\u2019s lymphoma study group","volume":"35","author":"Staiger","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.1991_bib5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"issue":"35","key":"10.1016\/j.annonc.2021.08.1991_bib6","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.19.00743","article-title":"Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium","volume":"37","author":"Rosenwald","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.annonc.2021.08.1991_bib7","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.annonc.2021.08.1991_bib8","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.annonc.2021.08.1991_bib9","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/annonc\/mdz386","article-title":"Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue","volume":"30","author":"Ciavarella","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.08.1991_bib10","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","article-title":"Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures","volume":"11","author":"Kotlov","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.1991_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-020-00404-0","article-title":"Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma","volume":"11","author":"Merdan","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.annonc.2021.08.1991_bib12","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined genetic inactivation of \u03b22-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.annonc.2021.08.1991_bib13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2021.08.1991_bib14","doi-asserted-by":"crossref","first-page":"103055","DOI":"10.1016\/j.ebiom.2020.103055","article-title":"Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces","volume":"61","author":"Sangaletti","year":"2020","journal-title":"EbioMed"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.1991_bib15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/2159-8290.CD-13-0276","article-title":"Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma","volume":"4","author":"Sangaletti","year":"2014","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1991_bib16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-019-0573-y","article-title":"A\u00a0novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL","volume":"34","author":"Staiger","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.annonc.2021.08.1991_bib17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2021.08.1991_bib18","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","article-title":"Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)","volume":"13","author":"Schmitz","year":"2012","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2021.08.1991_bib19","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjh.15710","article-title":"Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial","volume":"184","author":"Friedrichs","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1991_bib20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2021.08.1991_bib21","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","article-title":"Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma","volume":"32","author":"Held","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.08.1991_bib22","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/annonc\/mdu208","article-title":"Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL","volume":"25","author":"Murawski","year":"2014","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.annonc.2021.08.1991_bib23","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1200\/JCO.2013.54.6861","article-title":"Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"32","author":"Pfreundschuh","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2021.08.1991_bib24","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/leu.2015.43","article-title":"Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma","volume":"29","author":"Horn","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.annonc.2021.08.1991_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/19312450709336664","article-title":"Answering the call for a standard reliability measure for coding data","author":"Hayes","year":"2007","journal-title":"Commun Methods Meas"},{"key":"10.1016\/j.annonc.2021.08.1991_bib26","series-title":"Statistical Methods for Rates and Proportions","author":"Fleiss","year":"1981"},{"issue":"4","key":"10.1016\/j.annonc.2021.08.1991_bib27","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/ajcp\/aqw034","article-title":"Prognostic impact of tumor microenvironment in diffuse large B-cell lymphoma uniformly treated with R-CHOP chemotherapy","volume":"145","author":"Gomez-Gelvez","year":"2016","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1991_bib28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2009.07942.x","article-title":"Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP)","volume":"148","author":"Gratzinger","year":"2010","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.1991_bib29","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1186\/s12885-019-6208-x","article-title":"Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count","volume":"19","author":"Li","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.1991_bib30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1309\/AJCPJX4BJV9NLQHY","article-title":"The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"135","author":"Meyer","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"15","key":"10.1016\/j.annonc.2021.08.1991_bib31","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-14-3253","article-title":"The prognostic impact of CD163-positive macrophages in follicular lymphoma: a study from the BC cancer agency and the lymphoma study association","volume":"21","author":"Kridel","year":"2015","journal-title":"Clin Canc Res"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1991_bib32","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3324\/haematol.2014.113472","article-title":"Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial","volume":"100","author":"Riihij\u00e4rvi","year":"2015","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1991_bib33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3324\/haematol.2015.124008","article-title":"Tumor-associated macrophages in diffuse large B-cell lymphoma","volume":"100","author":"Kridel","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.annonc.2021.08.1991_bib34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","article-title":"PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas","volume":"14","author":"Goodman","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.1991_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/2162-3619-2-27","article-title":"The combined expression of the stromal markers fibronectin and SPARC improves the prediction of survival in diffuse large B-cell lymphoma","volume":"2","author":"Brandt","year":"2013","journal-title":"Exp Hematol Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2021.08.1991_bib36","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood-2012-05-430389","article-title":"A\u00a0new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma","volume":"120","author":"Perry","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.annonc.2021.08.1991_bib37","doi-asserted-by":"crossref","first-page":"101562","DOI":"10.1016\/j.isci.2020.101562","article-title":"A\u00a0spatially resolved dark- versus light-zone microenvironment signature subdivides germinal center-related aggressive B cell lymphomas","volume":"23","author":"Tripodo","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.annonc.2021.08.1991_bib38","doi-asserted-by":"crossref","first-page":"e28989","DOI":"10.4161\/onci.28989","article-title":"Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies","volume":"3","author":"Sangaletti","year":"2014","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.annonc.2021.08.1991_bib39","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1084\/jem.20030202","article-title":"Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma","volume":"198","author":"Sangaletti","year":"2003","journal-title":"J\u00a0Exp Med"},{"issue":"15","key":"10.1016\/j.annonc.2021.08.1991_bib40","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.annonc.2021.08.1991_bib41","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial","volume":"36","author":"Duhrsen","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.1991_bib42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00259-018-4103-3","article-title":"Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis","volume":"46","author":"Burggraaff","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.1991_bib43","doi-asserted-by":"crossref","first-page":"giaa016","DOI":"10.1093\/gigascience\/giaa016","article-title":"An image dataset related to automated macrophage detection in immunostained lymphoma tissue samples","volume":"9","author":"Wagner","year":"2020","journal-title":"GigaScience"},{"key":"10.1016\/j.annonc.2021.08.1991_bib44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12575-019-0098-9","article-title":"Automated macrophage counting in DLBCL tissue samples: a ROF filter based approach","volume":"21","author":"Wagner","year":"2019","journal-title":"Biol Proced Online"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421042757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421042757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:07:00Z","timestamp":1760335620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421042757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0923753421042757"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1991","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-\/triple-hit status","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1991","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}